Title
Category
Credits
Event date
Cost
Tweetorial: Parkinson’s Disease Psychosis: Current Therapies for Patients with PDP
  • Parkinson Disease
  • 0.25 AMA PRA Category 1 Credit™
  • 0.25 Participation
$0.00
Management for Parkinson's disease psychosis (PDP) includes evaluating triggers, non-Parkinson's drugs, Parkinson's drugs that may contribute to symptoms, behavioral interventions, and multidisciplinary collaboration between health providers.
Part 1: A Review of Schizophrenia
  • Schizophrenia/ Schizoaffective Disorders
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
$0.00
Schizophrenia affects 1% of the world’s population largely during a patient’s most productive years. Multiple treatments are available, however many gaps to recovery exist. Learn from experts diagnostic criteria for and defining recovery in schizophrenia.
Part 2: Chasing Cognitive and Negative Symptoms: Unmet Treatment Needs of Patients with Schizophrenia
  • Schizophrenia/ Schizoaffective Disorders
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
$0.00
Negative symptoms contribute to poor functional outcomes in schizophrenia. Evaluating different symptom domains and understanding the disorder’s reward circuitry can help with intervention and patients’ leading more fulfilling lives.
Part 3: Impact of Side Effects on Adherence to Schizophrenia Treatment
  • Schizophrenia/ Schizoaffective Disorders
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
$0.00
Side effects from medication have the greatest impact on adherence for patients with Schizophrenia. They lower quality of life, daily functioning, and satisfaction.
Patient-Specific Considerations, the GABA Pathway, and New Clinical Trial Data on Neuroactive Steroids in MDD and PPD
  • Depression
  • Major Depressive Disorder
  • Women’s Mental Health
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Participation
$0.00
Studies evaluating neuroactive steroid GABA-A receptor positive allosteric modulators demonstrate promising results for the treatment of MDD and PPD.
Diagnosing and Treating Alzheimer Disease During the Early Stage
  • Alzheimer Disease
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
$0.00
Many new therapies for early-stage AD have made their way onto the scene that can delay onset of the disease and/or slow down progression. Find out the how, what, when to better treat your patients with AD from specialists in the field.
Comparing LAI and Oral Antipsychotic Options: Expert Discussions with Schizophrenia Case Reports
  • Schizophrenia/ Schizoaffective Disorders
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
$0.00
LAI antipsychotics are often initiated late in adults with schizophrenia, despite evidence supporting early use. Experts discuss the barriers to initiating LAI treatment, as well as adherence, efficacy and safety data.
Agitation in Bipolar Disorder and Schizophrenia: Emergency Department Considerations
  • Bipolar Disorder
  • Schizophrenia/ Schizoaffective Disorders
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
$0.00
In treating agitation in bipolar disorder/schizophrenia in the emergency department, consider efficacy and safety of therapies as well as the safety of patient and staff.
Cognitive Impairment in Huntington Disease
  • Movement Disorders
  • Neurology
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
$0.00
An updated review of pathophysiology, emerging treatments, and supportive care strategies in the cognitive dimension of Huntington disease.
Tweetorial: Reviewing LAI vs. Oral Data in the Treatment of Schizophrenia
  • Schizophrenia/ Schizoaffective Disorders
  • 0.25 AMA PRA Category 1 Credit™
  • 0.25 Participation
$0.00
Experts compare data on hospitalization, adherence, relapse risk, tolerance and efficacy between LAIs and OAs in the treatment of schizophrenia.

Pages